Disease Category: Leukemia Trial Information

/Home/Leukemia Research/Clinical Trials for Leukemia

Disease Category: Leukemia Trial Information
CenterWatch

Dendritic/AML Fusion Cell Vaccine Therapy for AML Patients in First Remission: A Phase I Clinical Trial.

Study Description:
While many patients with AML achieve a remission with standard treatment, there is a high risk for relapse. We would like to see if a vaccine can stimulate an immune system reaction against the leukemia cells. We seek to enroll patients with newly diagnosed AML. Participants in this research study will have some of their own leukemia cells and immune stimulatory cells collected, fused together and stored to be given as a vaccine if they achieve a remission after standard treatment.

Study Criteria:

* Patients with bone-marrow biopsy confirmed diagnosis of AML .
* Patients must be at least 18 years old.
* Patients must give written informed consent in accordance with institutional and federal guidelines.
* Patients must not have received other immunotherapy treatment in the past three months.
* Patients must be without clinical evidence of CNS disease.
* Patients must not have clinically significant autoimmune disease.
* Patients must be HIV negative.

Adam Lerner, MD
Boston University Medical Center
Section of Hematology and Oncology
650 Albany Street, EBRC4
Boston MA 02118
Phone: 617-638-7504
Fax: 617-638-7530

The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Copyright © 2008 Jobson Medical Information LLC.